In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA. @RheumNow #EULAR2022 ABST#POS0331 https://t.co/pNL3Zlgmt7

RheumNow’s coverage of the #EULAR2022 annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its Faculty.

Rituximab/belimumab patients & COVID vaccination response: may have had average antibody response but there’s still the cellular response to consider too! Not as bad. Still caution++, but when ritux really needed we’ll find a way despite COVID from roundup #EULAR2022 @RheumNow https://t.co/zFr6QI9TOG

#OP0236 #EULAR2022 Prof Schulze-Koops highlighted a mechanistic study that baricitinib therapy ex vivo suppressed autophagy, increased apoptosis, and reduced expression of adhesion molecules in #sjogren salivary glands. Next step should be randomised controlled trial @RheumNow https://t.co/dirmHY9cYJ

Sex differences in axSpA: we’re continuing to better understand the differences in imaging findings. Existing MRI scoring may underserve axSpA in women. Added to therapy differences, a lot to readdress for our female axSpA patients. from roundup #EULAR2022 @RheumNow https://t.co/8wCKx9AFcM

#highlight n•1 💫 The presence of specific peripheral blood T cell sub-populations associated w/ disease flares in RA pts in remission after cs or bioDMARDs tapering or cessation identified in 2 different abstracts OP0011 and OP0074 @RheumNow #EULAR2022 https://t.co/SO2AgtkyTP

Gut microbiome of AS patients different from healthy controls. Different bacteria communities may be associated with disease activity. So much more to digest.... @RheumNow #EULAR2022 ABST#POS0330 https://t.co/EAvHngd6SD

#EULAR2022 POS0282 Febuxostat vs allopurinol: CV risk population study ⭐️16% reduction in all-cause mortality among febuxostat users, mostly non-CV death reduction ⭐️CV safety non-inferior to allopurinol @Rheumnow https://t.co/1oDSioQWPT

Stimakovits et al. Influence of placebo vs active comparator in RA clinical trials. ACR response rates systematically higher in studies with active comparators. ACR20 OR 1.64 (1.44-1.86), ACR50 OR 1.46 (1.28-1.71), ACR70 OR 1.61 (1.28-2.02) @RheumNow #EULAR2022 POS0563 https://t.co/x7PQH11oue

We’re in the #EULAR2022 highlights: basic/translational first. Wait, don’t go… because Temra cells are cool. Up in RA pts who are TNFi-IR, & may actually be more than a bystander. Understanding TNFi resistance is path to: predicting it knowing best what to do with it @RheumNow https://t.co/22Y6iinSbH

Psoriasis and Psoriatic arthritis patients have different circulating microRNA signatures compared to healthy controls. (miRNAs: non-coding RNAs controlling gene expression) PsO/PsA miRNAs involved in bone metabolism @RheumNow #EULAR2022 ABST#POS0314

#EULAR2022 POS0283: Do Rheums have Gout Stigma? ⭐️Stereotypes about pt related factors ⭐️Rheumatologists feel diet, exercise, wt loss more important in gout than RA, pharmacologic therapies less important than RA @Rheumnow

Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabrutinib groups vs 35.7% PBO. @RheumNow #EULAR2022 LB0005 https://t.co/u0UUWKal7n https://t.co/aYFf7Lpx1L

• EULAR Abstract Archive

PMR on the podium @profbdasgupta, with a positive phase 3! Sarilumab in relapsing PMR (SAPHYR): sari q2w+14w taper vs placebo+52w taper underrecruited 118/280 (COVID) but still hit primary, almost all secondary Better outcome + steroid-sparing: big LB0006 #EULAR2022 @RheumNow https://t.co/nd3TSibYa0